BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17674201)

  • 21. Analysis of the impact and burden of illness of adult chronic ITP in the US.
    Saleh MN; Fisher M; Grotzinger KM
    Curr Med Res Opin; 2009 Dec; 25(12):2961-9. PubMed ID: 19835465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managed care enrollment and chronically disabled women with breast cancer.
    Habermann EB; Virnig BA; Durham SB; Baxter NN
    Am J Manag Care; 2008 Aug; 14(8):514-20. PubMed ID: 18690767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
    Amonkar MM; Chastek B; Samant N; Teitelbaum A
    J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
    Hoy T; Singhal PK; Willey VJ; Insinga RP
    Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
    Stensland MD; Jacobson JG; Nyhuis A
    J Affect Disord; 2007 Aug; 101(1-3):187-93. PubMed ID: 17254637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
    Mehra M; Wu Y; Dhawan R
    J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
    Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
    Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
    DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
    J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland.
    Delcò F; Egger R; Bauerfeind P; Beglinger C
    Aliment Pharmacol Ther; 2005 Mar; 21(5):615-22. PubMed ID: 15740546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of care for new versus recurrent acute coronary syndrome patients.
    Shetty S; Halpern R; McCollam PL
    J Med Econ; 2008; 11(1):81-99. PubMed ID: 19450112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resource use and costs associated with different states of breast cancer.
    Lidgren M; Wilking N; Jönsson B; Rehnberg C
    Int J Technol Assess Health Care; 2007; 23(2):223-31. PubMed ID: 17493308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
    Korves C; Eldar-Lissai A; McHale J; Lafeuille MH; Hwa Ong S; Sheng Duh M
    J Med Econ; 2012; 15(5):925-37. PubMed ID: 22502902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
    Fillit H; Hill JW; Futterman R
    Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.